# US 9,039,994 B2 · Biomarkers for myocardial ischemia

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 9,039,994 B2
- Document ID: US9039994B2
- Status: Granted
- Kind: B2
- Application number: 13/953,226
- Filed: 2013-07-29
- Published: 2014-07-03
- Granted: 2015-05-26
- Earliest claimed: 2008-05-23
- Assignees: The Johns Hopkins University
- Applicants: The Johns Hopkins University
- Inventors: Jennifer Van Eyk; Simon Sheng; Qin Fu
- Web page: https://patentgrep.com/patent/US9039994B2

## CPC

- G01N 33/5308: {for analytes not provided for elsewhere, e.g. nucleic acids, uric acid, worms, mites}
- A61P 9/10: for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- G01N 33/573: for enzymes or isoenzymes
- G01N 33/6893: {related to diseases not provided for elsewhere}
- G01N 2400/40: Glycosaminoglycans, i.e. GAG or mucopolysaccharides, e.g. chondroitin sulfate, dermatan sulfate, hyaluronic acid, heparin, heparan sulfate, and related sulfated polysaccharides
- G01N 2800/324: Coronary artery diseases, e.g. angina pectoris, myocardial infarction
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

This invention relates, e.g., to a method for determining if a subject has myocardial ischemia, comprising (a) providing a blood sample obtained from a subject suspected of having myocardial ischemia; (b) determining in the sample the amount of one or more of the following proteins: (i) Lumican and/or (ii) Extracellular matrix protein 1 and/or (iii) Carboxypeptidase N; and (c) comparing the amount(s) of the protein(s) to a baseline value that is indicative of the amount of the protein in a subject that does not have myocardial ischemia, wherein a statistically significantly increased amount of the protein(s) compared to the baseline value is indicative of myocardial ischemia. Other proteins indicative of myocardial ischemia are also described, as are methods for treating a subject based on a diagnostic procedure of the invention, and kits for carrying out a method of the invention.

## Claims

### Claim 1

A kit for detecting the presence of myocardial ischemia in a subject, comprising reagents for detecting the amount of at least three of the following proteins:
i) Lumican, and/or
ii) Extracellular matrix protein 1, and/or
iii) Carboxypeptidase N, and/or
iv) Angiogenin, and/or
v) Semenogelin, and/or
vi) Long palate, lung and nasal epithelium carcinoma-associated protein 1, and/or
vii) Perioxiredoxin isoform 2, and/or
viii) Syntaxin 3, and/or
ix) S100 isoform A7, and/or
x) S100 isoform A8, and/or
xi) S100 isoform A9, and/or
xii) Sortilin-related receptor, and/or
xiii) Catalase, and/or
xiv) Low density lipoprotein receptor related protein 1, and/or
xv) Low density lipoprotein receptor related protein 2.

### Claim 2 (depends on 1)

The kit of claim 1, further comprising reagents for detecting the amount of at least one of the following proteins:
xvi) Hepatocyte growth factor activator, and/or
xvii) Alpha-2-HS-glycoprotein, and/or
xviii) Insulin like growth factor protein 6, and/or
xix) Galectin-7, and/or
xx) Hornerin, and/or
xxi) Proteoglycan-4, and/or
xxii) Profilaggrin (also referred to as Filaggrin), and/or
xxiii) Vitamin D binding protein, and/or
xxiv) C4b-binding protein alpha chain, and/or
xxv) Thyroxine binding globulin, and/or
xxvi) Alpha-2-glycoprotein 1, zinc, and/or
xxvii) Serine 3 protease, and/or
xxviii) Caspase 14, and/or
xxix) Desmogelin, and/or
xxx) Kininogen -1, and/or
xxxi) Hepatocyte growth factor like protein.